Press release
FAK Inhibitor Market Forecast 2032 by DelveInsight | Highlighting Key Players including Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim, Teva Pharmaceutical, and Immunocore
FAK Inhibitor Market
Key Takeaways from the FAK Inhibitors Market Report
• DelveInsight analysis shows that the FAK inhibitors market is expected to grow positively due to several underline factors during the study period (2019-2032).
• Globally, leading FAK inhibitors companies such as Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries, Immunocore, AstraZeneca, Genentech, and others are developing novel FAK inhibitors that can be available in the FAK inhibitors market in the coming years.
• Some key FAK inhibitors include VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others.
• Several FAK inhibitors are awaiting approval, while some FAK inhibitors are in the advanced stages of development.
Discover which FAK inhibitors are expected to grab the major FAK inhibitors market share @ https://www.delveinsight.com/report-store/fak-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
FAK Inhibitors Overview
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is overexpressed and activated in both adult and pediatric malignancies, where it plays critical roles in the regulation of pathogenesis and progression of the malignant phenotype. FAK operates in cancer in two ways: as a kinase activity in the cytoplasm, which is primarily dependent on integrin signaling, and as a scaffolding activity in the nucleus, which is accomplished through networking with various gene expressions. The FAK gene, also known as protein tyrosine kinase 2 (PTK2), is located on human chromosome 8q24.3 and encodes the FAK protein, which is found in many different types of cells and is mostly found in the plasma membrane and cytoplasm. FAK is classified into three domains: N-terminal FERM, core kinase, and C-terminal domains. The FAK FERM region is non-catalytic, and a similar FERM motif may be found in Janus kinase (JAK), another tyrosine kinase.
To know more about FAK inhibitors, visit @ https://www.delveinsight.com/sample-request/fak-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key FAK Inhibitors Drugs and Companies
• VS-6766 + defactinib: Verastem, Inc.
• Defactinib: Verastem, Inc.
• FAK Inhibitor GSK2256098: GlaxoSmithKline
• VS-6063: Verastem, Inc.
• Pembrolizumab: Merck Sharp & Dohme LLC
• PF-04554878: Pfizer
• IN10018: InxMed
• KIMMTRAK (tebentafusp): Immunocore
• ZEJULA (niraparib): GlaxoSmithKline
• LYNPARZA (olaparib): AstraZeneca
• AVASTIN (bevacizumab): Genentech
Learn more about the FDA-approved FAK inhibitors @ https://www.delveinsight.com/report-store/fak-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
FAK Inhibitors Market Dynamics
The dynamics of the FAK inhibitors market are expected to evolve as leading pharma and biotech companies around the world work hard to develop novel FAK choices with convenient RoA and a better safety profile to treat a wide range of malignancies. Furthermore, the FAK inhibitors pipeline is very robust; many potential therapies are being investigated for the treatment of various cancer, and it is safe to predict that the treatment space will significantly impact the oncology market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the FAK inhibitors market in the 7MM.
FAK Inhibitors Market Report Metrics
• Study Period: 2019-2032
• Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Base Year: 2019
• Key FAK Inhibitors Companies: Verastem, Inc., GlaxoSmithKline, Merck Sharp & Dohme LLC, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries, Immunocore, AstraZeneca, Genentech, and others
• Key FAK Inhibitors Therapies: VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others
Request for sample page@ https://www.delveinsight.com/sample-request/fak-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the FAK Inhibitors Market Report
• Therapeutic Assessment: Current Marketed and Emerging FAK Inhibitors
• FAK Inhibitors Market Dynamics: Attribute Analysis of Emerging FAK Inhibitors
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, FAK Inhibitors Market Access and Reimbursement
Discover more about FAK inhibitors in clinical trials @ https://www.delveinsight.com/sample-request/fak-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. FAK Inhibitors Market Key Insights
2. FAK Inhibitors Market Report Introduction
3. FAK Inhibitors Market Overview at a Glance
4. FAK Inhibitors Market Executive Summary
5. Disease Background and Overview
6. FAK Inhibitors Marketed Drugs
7. FAK Inhibitors Emerging Drugs
8. Seven Major FAK Inhibitors Market Analysis
9. FAK Inhibitors Market Outlook
10. Potential of Current and Emerging FAK Inhibitors Therapies
11. FAK Inhibitors KOL Views
12. FAK Inhibitors Market Drivers
13. FAK Inhibitors Market Barriers
14. FAK Inhibitors Unmet Needs
15. SWOT Analysis
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release FAK Inhibitor Market Forecast 2032 by DelveInsight | Highlighting Key Players including Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed, Amplia Therapeutics, Boehringer Ingelheim, Teva Pharmaceutical, and Immunocore here
News-ID: 3453258 • Views: …
More Releases from DelveInsight Business Research
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma …
The systemic lupus erythematosus (SLE) therapeutic landscape is undergoing a transformative shift, fueled by a surge in clinical research, innovative drug development strategies, and increased investment from global pharmaceutical leaders. With over 120 companies actively engaged and more than 140 pipeline therapies under development, the SLE clinical trial ecosystem is rapidly evolving toward precision medicine and targeted biologics.
DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight 2026" report delivers a comprehensive and data-driven…
EMB-001 Sales Forecast to 2034 Signals Breakthrough Opportunity in CUD Treatment …
The global addiction therapeutics landscape is on the brink of a paradigm shift as EMB-001, an innovative combination therapy, emerges as a promising solution for CUD and smoking withdrawal.
According to DelveInsight's latest report, "EMB-001 Sales Forecast and Market Size Analysis - 2034," the therapy is poised to unlock substantial market potential across the seven major markets (7MM), including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom,…
Excessive Daytime Sleepiness Pipeline 2026: FDA Updates, Therapy Innovations, an …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Excessive Daytime Sleepiness pipeline constitutes 10+ key companies continuously working towards developing 12+ Excessive Daytime Sleepiness treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Excessive Daytime Sleepiness Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Excessive Daytime Sleepiness…
Complicated Urinary Tract Infection Market 2034: Epidemiology Trends, Innovative …
DelveInsight's "Complicated Urinary Tract Infection Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Complicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Complicated Urinary Tract Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
More Releases for FAK
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
FAK ELISA Kits Market Outlook and Future Projections for 2030
The fak elisa kits market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Focal Adhesion Kinase Market Emerging Trend, Industry Demand and Regional Analys …
The global focal adhesion kinase market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The non-receptor tyrosine kinase focal adhesion kinase (FAK) provides signaling and scaffolding functions at integrin adhesion sites. It is involved in the management of the turnover of these adhesion sites, which is critical for cell migration control. FAK has been connected to cell defense against anoikis (suspension-induced cell death). FAK's ability…
FAK Inhibitor Market Poised for Significant Growth by 2034, Asserts DelveInsight …
(New York, USA) DelveInsight's FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the FAK Inhibitors Market Report
• DelveInsight analysis shows that the FAK inhibitors market is expected to grow positively due to several underline factors during the study period…
Focal Adhesion Kinase Market is Anticipated to Increase at a Stable CAGR over th …
Focal adhesion kinase market is anticipated to grow at a significant CAGR during the forecast period. The non-receptor tyrosine kinase focal adhesion kinase (FAK) provides signaling and scaffolding functions at integrin adhesion sites. It is involved in the management of the turnover of these adhesion sites, which is critical for cell migration control. FAK has been connected to cell defense against anoikis (suspension-induced cell death). FAK's ability to sequester receptor-interacting…
Pioneering FAK Inhibitor Market 2032 - DelveInsight's Comprehensive Analysis fea …
(New York, USA) DelveInsight's FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the FAK Inhibitors Market Report
• DelveInsight analysis shows that the FAK inhibitors market is expected to grow positively due to several underline factors during the study period (2019-2032).
• Globally,…
